EFdA-TP tetralithium

• CAT Number: I040051
• Molecular Formula: C12H14FLi4N5O12P3
• Molecular Weight: 559.95
• Purity: ≥95%
• InChI: InChI=1S/C12H15FN5O12P3.4Li/c1-2-12(4-27-32(23,24)30-33(25,26)29-31(20,21)22)6(19)3-7(28-12)18-5-15-8-9(14)16-11(13)17-10(8)18;;;;/h1,5-7,19H,3-4H2,(H,23,24)(H,25,26)(H2,14,16,17)(H2,20,21,22);;;;/q;;;;+1/p-1/t6-,7+,12+;;;;/m0..../s1
• InChIKey: AXBLDSHYWCXMSY-OCSZSNTDSA-M
• SMILES: [Li].[Li].[Li].[Li+].C#CC1(C(CC(O1)N2C=NC3=C(N=C(N=C32)F)N)O)COP(=O)([O-])OP(=O)(O)OP(=O)(O)O

EFdA-TP Tetralithium (Cat No.: I040051) is the active triphosphate form of EFdA (4′-ethynyl-2-fluoro-2′-deoxyadenosine), a potent nucleoside reverse transcriptase inhibitor (NRTI) with strong antiviral activity. It effectively inhibits HIV replication by targeting reverse transcriptase with high affinity and a long intracellular half-life. The tetralithium salt form enhances solubility and stability for biochemical and pharmacological studies. EFdA-TP is widely used in antiviral drug development, particularly in HIV research, to explore new therapeutic strategies and improve treatment efficacy against drug-resistant viral strains.

Reference

[1]. Eleftherios Michailidis, et al. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289(35):24533-48.
[Content Brief]